SciELO - Scientific Electronic Library Online

 
vol.16 número1Actitud y Conducta frente a la cuarta dosis de vacuna COVID-19 en personal de salud de la Región Lambayeque-2022.Producción científica en Scopus de los institutos de salud especializados públicos de Perú, 2010-2022 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo

versão impressa ISSN 2225-5109versão On-line ISSN 2227-4731

Resumo

ALVARADO-GAMARRA, Giancarlo et al. Clinical features and survival in pediatric oncohematological patients with COVID-19 in a referral Hospital of Peruvian Social Health Insurance, during 2020-2021. Rev. Cuerpo Med. HNAAA [online]. 2023, vol.16, n.1, pp.51-57.  Epub 27-Mar-2023. ISSN 2225-5109.  http://dx.doi.org/10.35434/rcmhnaaa.2023.161.1702.

Introduction:

In Latin America, there are few studies and heterogeneous results on pediatric oncohematology patients with COVID-19. Objective: To describe the clinical characteristics and survival of pediatric oncohematology patients with COVID-19 in a hospital in Lima-Peru, 2020-2021.

Methods:

Retrospective longitudinal study of hospitalized patients under 14 years of age. The data was collected from the medical records.

Results:

We included 30 patients, mostly men and schoolchildren, predominantly fever, respiratory and gastrointestinal symptoms, hematological neoplasia, and advanced oncological disease. The majority developed mild-moderate disease, but they also presented severe evolution requiring critical areas, with high mortality in hospitalization (13.3%) and low survival during follow-up (at 526 days, 59.26%, 95% CI 36 .53 to 76.20%). Survival increased with the start of chemotherapy, and decreased in patients in palliative condition, with respiratory support and shock.

Conclusion:

Most developed mild-moderate disease. However, SARS-CoV-2 can also cause severe involvement, death, and poor survival in oncohematological patients.

Palavras-chave : COVID-19; Neoplasms; leukemia; Child; Pediatrics, Peru.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )